Cambrex licenses drug R&D cell lines
Drug discovery company Cambrex' intention to enter a key segment of the drug discovery arena was substantiated by its purchase of immortalised cell lines, related technology and equipment.
Archives for January 19, 2005
Needle-free injector planned for hGH
UK company The Medical House has entered into a deal with Swiss biotechnology firm Serono for a needle-free injector system for the delivery of human growth hormone.
Applied Bio introduces superfast PCR system
Applied Biosystems has launched a polymerase chain reaction (PCR) system that allows real-time PCR runs to proceed three times faster. The system's quantitative results are available immediately without gel runs, purifying PCR products, or performing...
Avecia to spin out pharma specialist Reaxa
Fine and specialty chemicals company Avecia is planning to spin out part of its pharmaceutical technologies portfolio into a new company to be called Reaxa. The move should complete before the end of this quarter.
MBO agreed for Pharmaceutical Profiles
Early phase drug development specialist Pharmaceutical Profiles has a new management team following a £10 million buy-out.
A series of new appointments In-PharmaTechnologistcom provides a round-up – People on the move
New Year, new job. Busy times for personnel in the pharmaceutical technology sector, with a series of new appointments. In-PharmaTechnologist.com provides a round-up.
Sachet packer reaches UK market
UK packaging equipment supplier Isopak has introduced an all-in-one system designed to eliminate the difficulties of handling and packing pharmaceuticals, foods and cosmetics in sachets.
Nucleic acid drug market to reach €161bn?
A new report identifies the nucleic acid (NA) therapeutic market to reach over $210 billion (€161bn), illustrating a solid and potentially very profitable approach to treatment of cancer, rheumatoid arthritis, cardiovascular conditions, reports Wai...
Sigma-Aldrich to buy cell culture group JRH
Australia's CSL, the world's largest manufacturer of blood plasma products, has agreed to sell its JRH Biosciences division to Sigma-Aldrich for $370 million (€283m) in cash. JRH makes cell culture and sera products used in the production of...